Don't Give Up on Biosimilars-Congress Can Give Them a Boost: Drugs grown in live cells are hard to replicate. But policy changes can help accelerate the process.

IF 1.4 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

American Health and Drug Benefits Pub Date : 2019-09-01

Scott Gottlieb

引用次数: 0

Abstract Image

本刊更多论文

不要放弃生物仿制药——国会可以推动它们:在活细胞中生长的药物很难复制。但政策变化有助于加速这一进程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Health and Drug Benefits Medicine-Health Policy

CiteScore

2.90

自引率

0.00%

发文量

期刊介绍： AHDB welcomes articles on clinical-, policy-, and business-related topics relevant to the integration of the forces in healthcare that affect the cost and quality of healthcare delivery, improve healthcare quality, and ultimately result in access to care, focusing on health organization structures and processes, health information, health policies, health and behavioral economics, as well as health technologies, products, and patient behaviors relevant to value-based quality of care.